

35. A composition comprising glutamic acid decarboxylase in a pharmaceutically acceptable carrier for administration to a human patient.

C4 5u *H1* 49. (Amended) The method of claim 31, wherein the GAD is lower molecular weight GAD (GAD65).

50. The method of claim 31, wherein the GAD is recombinant GAD.

51. The method of claim 31, wherein the GAD is synthesized on a peptide synthesizer.

52. The method of claim 31, wherein the GAD is purified from the central nervous system tissue.

53. The method of claim 31, wherein the patient is a prediabetic patient having autoantibodies to GAD.

C3 5u *H1* 54. (Amended) The composition of claim 35, wherein the GAD is lower molecular weight (GAD65).

55. The composition of claim 35, wherein the GAD is recombinant GAD.

56. The composition of claim 35, wherein the GAD is synthesized on a peptide synthesizer.

57. The composition of claim 35, wherein the GAD is purified from the central nervous system tissue.

Please add the following new claims:

C4 5u *H1* 58. (New) The method of claim 31, wherein the GAD65 is human GAD65.
59. (New) The composition of claim 54, wherein the GAD65 is human GAD65.